0000898432-24-000462.txt : 20240605 0000898432-24-000462.hdr.sgml : 20240605 20240605100445 ACCESSION NUMBER: 0000898432-24-000462 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06c FILED AS OF DATE: 20240605 DATE AS OF CHANGE: 20240605 EFFECTIVENESS DATE: 20240605 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Island Pharmaceuticals Ltd CENTRAL INDEX KEY: 0002012855 ORGANIZATION NAME: IRS NUMBER: 000000000 STATE OF INCORPORATION: C3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-515176 FILM NUMBER: 241021111 BUSINESS ADDRESS: STREET 1: SUITE 201, 697 BURKE ROAD CITY: CAMBERWELL STATE: C3 ZIP: 3124 BUSINESS PHONE: 61390920475 MAIL ADDRESS: STREET 1: SUITE 201, 697 BURKE ROAD CITY: CAMBERWELL STATE: C3 ZIP: 3124 D 1 primary_doc.xml X0708 D LIVE 0002012855 Island Pharmaceuticals Ltd SUITE 201, 697 BURKE ROAD CAMBERWELL C3 AUSTRALIA 3124 61390920475 AUSTRALIA None None Corporation true 2020 Paul MacLeman Suite 201, 697 Burke Road Camberwell C3 AUSTRALIA 3124 Director David Foster Suite 201, 697 Burke Road Camberwell C3 AUSTRALIA 3124 Director PAC Partners Pty Ltd received a 6% fee on the Gross amount raised under the offer, plus 4,500,000 options David Brookes Suite 201, 697 Burke Road Camberwell C3 AUSTRALIA 3124 Director Albert Hansen Suite 201, 697 Burke Road Camberwell C3 AUSTRALIA 3124 Director Non-Executive Director Nick McCoy Suite 201, 697 Burke Road Camberwell C3 AUSTRALIA 3124 Executive Officer Vice President Clinical Product Development Biotechnology $1 - $1,000,000 06c false 2024-03-05 false true true false 0 1224405 1224405 0 Information in relation to total Offer, not USA only. Offer underwritten. To extent of the shortfall, underwriter and sub-underwriters subscribed for balance. 19 March 2024 company announcement. Total - $30,030.70 USD (0.6279 exch rate) from US residents false 4 73464 0 PAC Partners Pty Ltd received a 6% fee on the Gross amount raised under the offer, plus 4,500,000 options (0.6279 AUD-USD exchange rate) 0 false Island Pharmaceuticals Ltd /s/ Paul MacLeman Paul MacLeman Chair 2024-06-05